With August and the back-to-school season upon us, a large share of the outstanding second-quarter earnings results have been posted, and analysts and investors on Wall Street are very satisfied with the results. While plenty of investors remain very nervous, especially given the continuing big rally off the market lows and the lack of a 5% correction in almost a year, the \u201cbuy the dip\u201d crowd continues to hold serve, at least for now.<\/p>\n
In a series of new reports, Goldman Sachs has adjusted the price targets on some companies that may offer aggressive growth investors some parabolic upside potential. Given where they are currently trading, they probably offer far less downsized risk than many current trade ideas. It is important though to remember that no single analyst report should be used as a sole basis for any buying or selling decision.\n<\/p>\n
This company sometimes is confused with a biotech with a similar name that Pfizer bought in 2019. Array Technologies Inc. (NASDAQ: ARRY) provides solar tracking solutions and services for utility-scale projects. Its products include DuraTrack HZ v3, a single-axis solar tracking system, and SmarTrack, a machine learning software that automatically adjusts module angles in response to weather and site conditions.<\/p>\n
This stock had a red-hot initial public offering last fall. Shares charged out of the gate, as the first trade was 34% above where the upsized IPO was priced. A total of 47.5 million shares were sold in the offering, as the maker of ground-mounting systems used in solar energy projects sold 7 million shares to raise $154 million and a selling shareholder sold 40.5 million shares.<\/p>\n
Since then it has been a nightmare for investors, but Goldman Sachs thinks the bottom has been found and noted this about the stock’s potential:<\/p>\n
\nArray Technologies posted weak 2Q21 results as expected given higher steel and freight costs which forced the company to withdraw guidance and re-engage with customers on a multitude of open contracts last quarter. Encouragingly, the company has not seen any cancellations to date, and appears to have executed through the challenging cost environment with demand intact, prompting a reinstatement of guidance metrics for 2021, as well as acknowledgment that 3Q21 will mark a trough for margins.<\/p>\n
Looking ahead, backlog trends plus some amount of project pushouts bode well for a strong 2022 top-line, in our view, while on margins ARRY cited that new orders since May have been booking at low-20% gross margins, in line with pre-inflationary levels. Though execution remains key, we believe the risk-reward continues to remain favorable for investors willing to exercise some amount of patience on the pace of the recovery trade in Array shares. We remain Buy rated and highlight our key takeaways in more detail within.<\/p>\n<\/blockquote>\n
Goldman Sachs lowered the $28 price target to $24, while the Wall Street consensus target is $27.70. Thursday’s close at $17.30 a share was up almost 13% on the day to the Goldman Sachs commentary. Hitting the firm’s price target would be a massive 56% gain.<\/p>\n